5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors

JING TANG, Andrew D. Huber, Dallas L. Pineda, Kelsey N. Boschert, Jennifer J. Wolf, Jayakanth Kankanala, Jiashu Xie, Stefan G. Sarafianos, Zhengqiang Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Chronic hepatitis B virus (HBV) infection represents a major health threat. Current FDA-approved drugs do not cure HBV. Targeting HBV core protein (Cp) provides an attractive approach toward HBV inhibition and possibly infection cure. We have previously identified and characterized a 5-amino-3-methylthiophene-2,4-dicarboxamide (ATDC) compound as a structurally novel hit for capsid assembly effectors (CAEs). We report herein hit validation through studies on absorption, distribution, metabolism and excretion (ADME) properties and pharmacokinetics (PK), and hit optimization via analogue synthesis aiming to probe the structure-activity relationship (SAR) and structure-property relationship (SPR). In the end, these medicinal chemistry efforts led to the identification of multiple analogues strongly binding to Cp, potently inhibiting HBV replication in nanomolar range without cytotoxicity, and exhibiting good oral bioavailability (F). Two of our analogues, 19o (EC50 = 0.11 μM, CC50 > 100 μM, F = 25%) and 19k (EC50 = 0.31 μM, CC50 > 100 μM, F = 46%), displayed overall lead profiles superior to reported CAEs 7–10 used in our studies.

Original languageEnglish (US)
Pages (from-to)179-192
Number of pages14
JournalEuropean Journal of Medicinal Chemistry
Volume164
DOIs
StatePublished - Feb 15 2019

Fingerprint

Virus Assembly
Capsid
Viruses
Hepatitis B virus
Viral Core Proteins
Pharmacokinetics
Cytotoxicity
Metabolism
Pharmaceutical Chemistry
Validation Studies
Chronic Hepatitis B
Virus Diseases
Structure-Activity Relationship
Virus Replication
Biological Availability
Health
Pharmaceutical Preparations
Infection
Proteins
FM 100

PubMed: MeSH publication types

  • Journal Article

Cite this

5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors. / TANG, JING; Huber, Andrew D.; Pineda, Dallas L.; Boschert, Kelsey N.; Wolf, Jennifer J.; Kankanala, Jayakanth; Xie, Jiashu; Sarafianos, Stefan G.; Wang, Zhengqiang.

In: European Journal of Medicinal Chemistry, Vol. 164, 15.02.2019, p. 179-192.

Research output: Contribution to journalArticle

TANG, JING, Huber, AD, Pineda, DL, Boschert, KN, Wolf, JJ, Kankanala, J, Xie, J, Sarafianos, SG & Wang, Z 2019, '5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors', European Journal of Medicinal Chemistry, vol. 164, pp. 179-192. https://doi.org/10.1016/j.ejmech.2018.12.047
TANG, JING ; Huber, Andrew D. ; Pineda, Dallas L. ; Boschert, Kelsey N. ; Wolf, Jennifer J. ; Kankanala, Jayakanth ; Xie, Jiashu ; Sarafianos, Stefan G. ; Wang, Zhengqiang. / 5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors. In: European Journal of Medicinal Chemistry. 2019 ; Vol. 164. pp. 179-192.
@article{17f9e8d1b3834982b1a5792f8715ab18,
title = "5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors",
abstract = "Chronic hepatitis B virus (HBV) infection represents a major health threat. Current FDA-approved drugs do not cure HBV. Targeting HBV core protein (Cp) provides an attractive approach toward HBV inhibition and possibly infection cure. We have previously identified and characterized a 5-amino-3-methylthiophene-2,4-dicarboxamide (ATDC) compound as a structurally novel hit for capsid assembly effectors (CAEs). We report herein hit validation through studies on absorption, distribution, metabolism and excretion (ADME) properties and pharmacokinetics (PK), and hit optimization via analogue synthesis aiming to probe the structure-activity relationship (SAR) and structure-property relationship (SPR). In the end, these medicinal chemistry efforts led to the identification of multiple analogues strongly binding to Cp, potently inhibiting HBV replication in nanomolar range without cytotoxicity, and exhibiting good oral bioavailability (F). Two of our analogues, 19o (EC50 = 0.11 μM, CC50 > 100 μM, F = 25{\%}) and 19k (EC50 = 0.31 μM, CC50 > 100 μM, F = 46{\%}), displayed overall lead profiles superior to reported CAEs 7–10 used in our studies.",
author = "JING TANG and Huber, {Andrew D.} and Pineda, {Dallas L.} and Boschert, {Kelsey N.} and Wolf, {Jennifer J.} and Jayakanth Kankanala and Jiashu Xie and Sarafianos, {Stefan G.} and Zhengqiang Wang",
year = "2019",
month = "2",
day = "15",
doi = "10.1016/j.ejmech.2018.12.047",
language = "English (US)",
volume = "164",
pages = "179--192",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - 5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors

AU - TANG, JING

AU - Huber, Andrew D.

AU - Pineda, Dallas L.

AU - Boschert, Kelsey N.

AU - Wolf, Jennifer J.

AU - Kankanala, Jayakanth

AU - Xie, Jiashu

AU - Sarafianos, Stefan G.

AU - Wang, Zhengqiang

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Chronic hepatitis B virus (HBV) infection represents a major health threat. Current FDA-approved drugs do not cure HBV. Targeting HBV core protein (Cp) provides an attractive approach toward HBV inhibition and possibly infection cure. We have previously identified and characterized a 5-amino-3-methylthiophene-2,4-dicarboxamide (ATDC) compound as a structurally novel hit for capsid assembly effectors (CAEs). We report herein hit validation through studies on absorption, distribution, metabolism and excretion (ADME) properties and pharmacokinetics (PK), and hit optimization via analogue synthesis aiming to probe the structure-activity relationship (SAR) and structure-property relationship (SPR). In the end, these medicinal chemistry efforts led to the identification of multiple analogues strongly binding to Cp, potently inhibiting HBV replication in nanomolar range without cytotoxicity, and exhibiting good oral bioavailability (F). Two of our analogues, 19o (EC50 = 0.11 μM, CC50 > 100 μM, F = 25%) and 19k (EC50 = 0.31 μM, CC50 > 100 μM, F = 46%), displayed overall lead profiles superior to reported CAEs 7–10 used in our studies.

AB - Chronic hepatitis B virus (HBV) infection represents a major health threat. Current FDA-approved drugs do not cure HBV. Targeting HBV core protein (Cp) provides an attractive approach toward HBV inhibition and possibly infection cure. We have previously identified and characterized a 5-amino-3-methylthiophene-2,4-dicarboxamide (ATDC) compound as a structurally novel hit for capsid assembly effectors (CAEs). We report herein hit validation through studies on absorption, distribution, metabolism and excretion (ADME) properties and pharmacokinetics (PK), and hit optimization via analogue synthesis aiming to probe the structure-activity relationship (SAR) and structure-property relationship (SPR). In the end, these medicinal chemistry efforts led to the identification of multiple analogues strongly binding to Cp, potently inhibiting HBV replication in nanomolar range without cytotoxicity, and exhibiting good oral bioavailability (F). Two of our analogues, 19o (EC50 = 0.11 μM, CC50 > 100 μM, F = 25%) and 19k (EC50 = 0.31 μM, CC50 > 100 μM, F = 46%), displayed overall lead profiles superior to reported CAEs 7–10 used in our studies.

UR - http://www.scopus.com/inward/record.url?scp=85059147386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059147386&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2018.12.047

DO - 10.1016/j.ejmech.2018.12.047

M3 - Article

C2 - 30594676

AN - SCOPUS:85059147386

VL - 164

SP - 179

EP - 192

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -